Revolution Medicines (RVMD) Non-Current Assets (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Non-Current Assets of $285.8 million for Q1 2026, up 23.86% year-over-year from $230.8 million in Q1 2025, and up 2.27% quarter-over-quarter from $279.5 million in Q4 2025.
Revolution Medicines (RVMD) Non-Current Assets (2019 - 2026) Analysis & Trends
Revolution Medicines' Non-Current Assets history runs 8 years deep, the most recent figure standing at $285.8 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 23.86% year-over-year to $285.8 million; the TTM figure through Mar 2026 stood at $1.1 billion (up 218.33% YoY), while the FY2025 annual figure was $279.5 million, up 21.16% from the prior year.
- Non-Current Assets for Q1 2026 stood at $285.8 million, up from $279.5 million in the prior quarter.
- The five-year high for Non-Current Assets was $285.8 million in Q1 2026, with the low at -$1.6 billion in Q2 2024.
- The 5-year median for Non-Current Assets is $179.2 million (2024), against an average of $93.7 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets sank 1134.73% in 2024, then soared 116.13% in 2025.
- Revolution Medicines' Non-Current Assets stood at $151.7 million in 2022, then grew by 20.22% to $182.4 million in 2023, then rose by 26.45% to $230.7 million in 2024, then advanced by 21.16% to $279.5 million in 2025, then increased by 2.27% to $285.8 million in 2026.
- Business Quant data shows RVMD's Non-Current Assets at $285.8 million in Q1 2026, $279.5 million in Q4 2025, and $274.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 564.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 294.93 Mn |
| Mar 31, 2026 | 285.82 Mn |
| Dec 31, 2025 | 279.47 Mn |
| Sep 30, 2025 | 274.43 Mn |
| Jun 30, 2025 | 253.13 Mn |
| Mar 31, 2025 | 230.77 Mn |
| Dec 31, 2024 | 230.67 Mn |
| Sep 30, 2024 | 183.86 Mn |
| Jun 30, 2024 | -1.57 Bn |
| Mar 31, 2024 | 179.16 Mn |
| Dec 31, 2023 | 182.42 Mn |
| Sep 30, 2023 | 159.77 Mn |
| Jun 30, 2023 | 151.62 Mn |
| Mar 31, 2023 | 150.50 Mn |
| Dec 31, 2022 | 151.75 Mn |
| Sep 30, 2022 | 150.80 Mn |
| Jun 30, 2022 | 149.76 Mn |
| Mar 31, 2022 | 148.43 Mn |
| Dec 31, 2021 | 148.22 Mn |
| Sep 30, 2021 | 111.44 Mn |